Posts by: admin

News

Bristol-Myers Squibb (BMS) has signed an agreement to acquire Austrian biotech F-star Alpha, and claim rights to FS102, its investigational drug targeting HER2-positive breast and stomach cancers. BMS will pay $50m ... Read more

October 21, 2014October 21, 2014

NewLink Genetics And Genentech Collaborate To Develop Next Generation IDO/TDO Inhibitors

News

NewLink Genetics Corporation has announced the beginning of an exclusive license agreement with Genentech for the development of NLG919, an IDO pathway inhibitor. Furthermore, both companies will also collaborate in the ... Read more

October 15, 2014October 15, 2014

FDA Approves Avastin For Treatment of Metastatic Carcinoma of The Cervix

News

The U.S. Food and Drug Administration (FDA) has approved Genentech’s Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan, for the treatment of women with persistent, recurrent ... Read more

October 14, 2014October 14, 2014

Study Optimizes Platform to Expand Tumor Infiltrating Lymphocytes (TILs) For Melanoma Treatment

News

In a recent study titled “Activation and Propagation of Tumor-infiltrating Lymphocytes on Clinical-grade Designer Artificial Antigen-presenting Cells for Adoptive Immunotherapy of Melanoma” published in the Journal of Immunotherapy, a team ... Read more

October 13, 2014October 13, 2014

Amgen’s Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia

News

Amgen, a biotechnology company developing and delivering innovative human therapeutics, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for blinatumomab, the investigational ... Read more

October 10, 2014October 10, 2014

An American Journal of Managed Care Panel Explores Immuno-oncology

News

A panel of researchers assembled by The American Journal of Managed Care discussed the current state of immuno-oncology in the treatment of cancer. Surabhi Dangi-Garimella, PhD, managing editor of Evidence-Based Oncology, ... Read more

October 9, 2014October 9, 2014

Tumour Infiltrating Lymphocytes for Cancer Treatment and Prognosis

News

During the European Society for Medical Oncology (ESMO) congress 2014, Madrid, different studies highlighted the importance of tumor infiltrating lymphocytes (TILs) in cancer prognostic and treatment. The tumor microenvironment is ... Read more

October 8, 2014October 8, 2014

Novartis And Bristol-Myers Squibb Collaborate to Test Novel Immunotherapy Combination for NSCLC

News

Two major international pharmaceutical companies, Novartis and Bristol-Myers Squibb Company, have announced a collaboration to assess the safety, tolerability and efficacy of three investigational drugs, Zykadia, INC280 and EGF816, with ... Read more

October 6, 2014

Prima BioMed Buys Immuno-Oncology Firm Immutep

News

Prima Biomed Ltd, a leader in the development of personalized immunocellular therapeutic products for the treatment of cancer, has announced an important investment agreement of more than $2.5 million with ... Read more

October 3, 2014

EU Reviews Opdivo for Lung Cancer Treatment

News

Bristol-Myers Squibb’s new investigational drug Opdivo, or nivolumab, already under review in the U.S. and E.U. for the treatment of advanced melanoma, is now being reviewed in the EU for ... Read more